---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-23-000008"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T23:08:55.558734+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q4 revenue $177.8M (+11% YoY); GAAP EPS $(0.52), adjusted EPS $(0.12)

## Summary
- Q4 testing volumes up 26% YoY; hereditary cancer +16%, GeneSight +23%.
- Full-year 2022 GeneSight revenue grew 36% to $127.6M.
- FY2023 guidance: revenue $720-750M, adjusted EPS $(0.40)-$(0.20).
- Q1 2023 guidance: revenue $170-172M, adjusted EPS $(0.20)-$(0.18).
- Ended Q4 with $169.7M cash, no debt; cash used in ops $7.7M.

## SEC filing metadata
- accession: 0000899923-23-000008
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992323000008/0000899923-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992323000008/mygn-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-23-000008
- JSON: https://secwatch.observer/filing/0000899923-23-000008.json
- Plain text: https://secwatch.observer/filing/0000899923-23-000008.txt

## Key facts
- Earnings Releases
  MYRIAD GENETICS INC reported fourth quarter ended December 31, 2022 results: revenue $177.8 million, EPS $(0.52). Guidance initiated.
  - Period: fourth quarter ended December 31, 2022
  - Revenue: $177.8 million
  - EPS: $(0.52)
  - Guidance: initiated
  - Result: reported results
  source text: Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992323000008/0000899923-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.